The catastrophic antiphospholipid syndrome in children

Area of Science:

• Rheumatology
• Pediatric Immunology
• Thrombosis Research

Background:

• Catastrophic antiphospholipid syndrome (CAPS) is a severe, antibody-mediated condition characterized by diffuse microvascular thrombosis.
• While rare in childhood, CAPS presents a significant diagnostic and therapeutic challenge with high mortality rates.
• Understanding the interplay of infection, antiphospholipid antibodies, and complement activation is key to managing pediatric CAPS.

Purpose of the Study:

• To review current understanding of catastrophic antiphospholipid syndrome (CAPS), focusing on pediatric cases.
• To highlight recent advancements in the diagnosis, pathogenesis, and treatment strategies for CAPS.
• To emphasize the critical need for early recognition and aggressive management in pediatric CAPS.

Main Methods:

• Review of recent literature, including case reports and registry data.
• Analysis of factors contributing to pediatric CAPS, such as infection and antiphospholipid antibodies.
• Evaluation of treatment modalities, including anticoagulation, anti-inflammatory agents, and complement inhibition.

Main Results:

• Pediatric CAPS is infrequently reported, with most data derived from case studies and registries.
• Infection and antiphospholipid antibodies are primary triggers, with complement activation playing a role in microvascular thrombosis.
• Limited studies suggest complement inhibition improves outcomes, and managing autoantibody production is vital for long-term care.

Conclusions:

• CAPS is a rare but highly fatal (33-50% mortality) pediatric autoimmune disease affecting the microvasculature.
• Prompt recognition and aggressive, multimodal treatment are essential for managing pediatric CAPS.
• Treatment strategies include anticoagulation, anti-inflammatory therapy, infection eradication, and addressing pathogenic autoantibodies.